Downregulation of Serine Protease HTRA1 Is Associated with Poor Survival in Breast Cancer

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Lehner, Anna ^a   Magdolen, Viktor ^a   Schuster, Tibor ^b   Kotzsch, Matthias ^c   Kiechle, Marion ^a   Meindl, Alfons ^a   Sweep, Fred C G J ^d   Span, Paul N ^d   Gross, Eva ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SERINE PROTEINASE;

ADULT; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HTRA1 GENE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROMOTER REGION; RECURRENCE FREE SURVIVAL; VALIDATION PROCESS;

ADULT; AGED; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA METHYLATION; DOWN-REGULATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SERINE ENDOPEPTIDASES;

EID: 84875971200     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060359     Document Type: Article

References (40)

1. Zumbrunn J, Trueb B (1996) Primary structure of a putative serine protease specific for IGF-binding proteins. FEBS Lett 398: 187-192. S0014-5793(96)01229-X [pii].
2. Malet H, Canellas F, Sawa J, Yan J, Thalassinos K, et al. (2012) Newly folded substrates inside the molecular cage of the HtrA chaperone DegQ. Nat Struct Mol Biol 19: 152-157. nsmb.2210 [pii];10.1038/nsmb.2210 [doi].
3. Singh N, Kuppili RR, Bose K (2011) The structural basis of mode of activation and functional diversity: a case study with HtrA family of serine proteases. Arch Biochem Biophys 516: 85-96. S0003-9861(11)00344-4 [pii];10.1016/j.abb.2011.10.007 [doi].
4. Spiess C, Beil A, Ehrmann M (1999) A temperature-dependent switch from chaperone to protease in a widely conserved heat shock protein. Cell 97: 339-347. S0092-8674(00)80743-6 [pii].
5. Polur I, Lee PL, Servais JM, Xu L, Li Y, (2010) Role of HTRA1, a serine protease, in the progression of articular cartilage degeneration. Histol Histopathol 25: 599-608.
6. Hu SI, Carozza M, Klein M, Nantermet P, Luk D, et al. (1998) Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J Biol Chem 273: 34406-34412.
7. Ajayi F, Kongoasa N, Gaffey T, Asmann YW, Watson WJ, et al. (2008) Elevated expression of serine protease HtrA1 in preeclampsia and its role in trophoblast cell migration and invasion. Am J Obstet Gynecol 199: 557-10. S0002-9378(08)00498-5 [pii];10.1016/j.ajog.2008.04.046 [doi].
8. Hara K, Shiga A, Fukutake T, Nozaki H, Miyashita A, et al. (2009) Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med 360: 1729-1739. 360/17/1729 [pii];10.1056/NEJMoa0801560 [doi].
9. Shiga A, Nozaki H, Yokoseki A, Nihonmatsu M, Kawata H, et al. (2011) Cerebral small-vessel disease protein HTRA1 controls the amount of TGF-beta1 via cleavage of proTGF-beta1. Hum Mol Genet 20: 1800-1810. ddr063 [pii];10.1093/hmg/ddr063 [doi].
10. Chien J, Ota T, Aletti G, Shridhar R, Boccellino M, et al. (2009) Serine protease HtrA1 associates with microtubules and inhibits cell migration. Mol Cell Biol 29: 4177-4187. MCB.00035-09 [pii];10.1128/MCB.00035-09 [doi].
11. Baldi A, De LA, Morini M, Battista T, Felsani A, et al. (2002) The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 21: 6684-6688. 10.1038/sj.onc.1205911 [doi].
12. Chien J, Staub J, Hu SI, Erickson-Johnson MR, Couch FJ, et al. (2004) A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene 23: 1636-1644. 10.1038/sj.onc.1207271 [doi];1207271 [pii].
13. Mullany SA, Moslemi-Kebria M, Rattan R, Khurana A, Clayton A, et al. (2011) Expression and functional significance of HtrA1 loss in endometrial cancer. Clin Cancer Res 17: 427-436. 1078-0432.CCR-09-3069 [pii];10.1158/1078-0432.CCR-09-3069 [doi].
14. Bowden MA, Di Nezza-Cossens LA, Jobling T, Salamonsen LA, Nie G (2006) Serine proteases HTRA1 and HTRA3 are down-regulated with increasing grades of human endometrial cancer. Gynecol Oncol 103: 253-260. S0090-8258(06)00220-4 [pii];10.1016/j.ygyno.2006.03.006 [doi].
15. Wang N, Eckert KA, Zomorrodi AR, Xin P, Pan W, et al. (2012) Down-Regulation of HtrA1 Activates the Epithelial-Mesenchymal Transition and ATM DNA Damage Response Pathways. PLoS One 7: e39446. 10.1371/journal.pone.0039446 [doi];PONE-D-11-16563 [pii].
16. Baldi A, Mottolese M, Vincenzi B, Campioni M, Mellone P, et al. (2008) The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomics 9: 1069-1077. 10.2217/14622416.9.8.1069 [doi].
17. Zhu F, Jin L, Luo TP, Luo GH, Tan Y, Qin XH (2010) Serine protease HtrA1 expression in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 9: 508-512. 1402 [pii].
18. Chien J, Aletti G, Baldi A, Catalano V, Muretto P, et al. (2006) Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest 116: 1994-2004. 10.1172/JCI27698 [doi].
19. Catalano V, Mellone P, d'Avino A, Shridhar V, Staccioli MP, et al. (2011) HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer. Histopathology 58: 669-678. 10.1111/j.1365-2559.2011.03818.x [doi].
20. He X, Khurana A, Maguire JL, Chien J, Shridhar V (2012) HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation. Int J Cancer 130: 1029-1035. 10.1002/ijc.26044 [doi].
21. He X, Ota T, Liu P, Su C, Chien J, et al. (2010) Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res 70: 3109-3118. 0008-5472.CAN-09-3557 [pii];10.1158/0008-5472.CAN-09-3557 [doi].
22. Campioni M, Severino A, Manente L, De LA, La PR, et al. (2011) Identification of protein-protein interactions of human HtrA1. Front Biosci (Elite Ed) 3: 1493-1499. 350 [pii].
23. Mauney J, Olsen BR, Volloch V (2010) Matrix remodeling as stem cell recruitment event: a novel in vitro model for homing of human bone marrow stromal cells to the site of injury shows crucial role of extracellular collagen matrix. Matrix Biol 29: 657-663. S0945-053X(10)00133-2 [pii];10.1016/j.matbio.2010.08.008 [doi].
24. Holzscheiter L, Biermann JC, Kotzsch M, Prezas P, Farthmann J, et al. (2006) Quantitative reverse transcription-PCR assay for detection of mRNA encoding full-length human tissue kallikrein 7: prognostic relevance of KLK7 mRNA expression in breast cancer. Clin Chem 52: 1070-1079. clinchem.2005.065599 [pii];10.1373/clinchem.2005.065599 [doi].
25. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CG (2003) Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 22: 4898-4904. 10.1038/sj.onc.1206818 [doi];1206818 [pii].
26. Farthmann J, Holzscheiter L, Biermann J, Meye A, Luther T, et al. (2004) Development of quantitative RT-PCR assays for wild-type urokinase receptor (uPAR-wt) and its splice variant uPAR-del5. Rad Oncol 38: 111-119.
27. Sato S, Kopitz C, Grismayer B, Beaufort N, Reuning U, et al. (2011) Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 127: 649-657. 10.1007/s10549-010-1042-5 [doi].
28. Hothorn T, Lausen B, (2002) Maximally Selected Rank Statistics in R. R News. 2/1: 3-5.
29. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, et al. (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123: 725-731. 10.1007/s10549-009-0674-9 [doi].
30. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M., et al. (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100: 229-235. 10.1007/s10549-006-9242-8 [doi].
31. Narkiewicz J, Lapinska-Szumczyk S, Zurawa-Janicka D, Skorko-Glonek J, Emerich J, et al. (2009) Expression of human HtrA1, HtrA2, HtrA3 and TGF-beta1 genes in primary endometrial cancer. Oncol Rep 21: 1529-1537.
32. Zurawa-Janicka D, Kobiela J, Stefaniak T, Wozniak A, Narkiewicz J, et al. (2008) Changes in expression of serine proteases HtrA1 and HtrA2 during estrogen-induced oxidative stress and nephrocarcinogenesis in male Syrian hamster. Acta Biochim Pol 55: 9-19. 20081581 [pii].
33. Gnant M, Harbeck N, Thomssen C (2011) St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel) 6: 136-141. 10.1159/000328054 [doi];000328054 [pii].
34. Folgueira MA, Carraro DM, Brentani H, Patrao DF, Barbosa EM, et al. (2005) Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11: 7434-7443. 11/20/7434 [pii];10.1158/1078-0432.CCR-04-0548 [doi].
35. Ahmed N, Abubaker K, Findlay J, Quinn M (2010) Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 10: 268-278. EPub-Abstract-CCDT-23 [pii].
36. Esposito V, Campioni M, De LA, Spugnini EP, Baldi F, et al. (2006) Analysis of HtrA1 serine protease expression in human lung cancer. Anticancer Res 26: 3455-3459.
37. Katsuno Y, Lamouille S, Derynck R (2013) TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25: 76-84. 10.1097/CCO.0b013e32835b6371 [doi].
38. Lv ZD, Kong B, Li JG, Qu HL, Wang XG, et al. (2013) Transforming growth factor-beta 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition. Oncol Rep 29: 219-225. 10.3892/or.2012.2111 [doi].
39. Fang Y, Chen Y, Yu L, Zheng C, et al. (2013) Inhibition of Breast Cancer Metastases by a Novel Inhibitor of TGFbeta Receptor 1. J Natl Cancer Inst 105: 47-58. djs485 [pii];10.1093/jnci/djs485 [doi].
40. Zupkovitz G, Tischler J, Posch M, Sadzak I, Ramsauer K, et al. (2006) Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol Cell Biol 26: 7913-7928. MCB.01220-06 [pii];10.1128/MCB.01220-06 [doi].